Argus Research analyst Chris Graja maintained a Buy rating on CVS Health (CVS – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $54.91.
According to TipRanks, Graja is a 5-star analyst with an average return of 13.2% and a 73.17% success rate. Graja covers the Consumer Cyclical sector, focusing on stocks such as Dollar General, Home Depot, and KB Home.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CVS Health with a $70.94 average price target, representing a 29.19% upside. In a report released yesterday, Truist Financial also maintained a Buy rating on the stock with a $66.00 price target.
Based on CVS Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $93.81 billion and a net profit of $2.05 billion. In comparison, last year the company earned a revenue of $83.85 billion and had a net profit of $2.3 billion
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CVS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVS Health (CVS) Company Description:
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.
